Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESENT: NeuVax for prevention of recurrence in early-stage node-positive breast cancer with low to intermediate HER2 expression
2011-005219-98Phase 3Terminated
- Sponsor
- Galena Biopharma
- Start
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nelipepimut-S in breast cancer (2 arms), sponsored by Galena Biopharma. Primary endpoint: Disease-free survival (DFS). Started Jun 2012; status: terminated.
02
Drugs
nelipepimut-S
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005219-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005219-98.